The global demand for Peptide Drug Conjugates Market is presumed to reach the market size of nearly USD 10.32 BN by 2030 from USD 1.25 BN in 2022 with a CAGR of 30.17% under the study period 2022 - 2030. Regarding volume, the market was calculated XX Kilo Tons in 2022 and forecast to touch XX Kilo Tons by 2030 with a CAGR of XX% during 2023-2030.
Peptide drug conjugates (PDC) are essentially made up of a homing peptide, a linker, and a cytotoxic payload. PDC uses a peptide chain of roughly ten amino acids to target tumour cells. To release the cytotoxin, it targets the tumour cell. It has a lower molecular weight than antibody-drug conjugates (ADCs), which can quickly enrich tumour locations. Additionally, medication molecules in blood have a short half-life and can be removed quickly, minimizing hazardous side effects brought on by off-targeting.
The market for peptide-drug conjugates (PDCs) is expecting high growth due to the rising demand for therapeutic medications, the high prevalence of cancer disorders, the increase in clinical trials, and increased investments by major market participants in the creation of effective treatments.A growing number of people concerned with their health, population increase, and advanced medical technologies contribute to the market's expansion. However, the market expansion is constrained by expensive treatments, difficult procedures, and lax regulatory regulations. Nonetheless, it is expected that using Peptide-Drug Conjugates (PDCs) therapy for patients with various cancers would lead to several clinical possibilities. The need for a more effective treatment strategy, such as targeted PDCs, has been escalated by the tumour cells' rising drug resistance to such medicines, propelling the market for peptide drug conjugates.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of peptide drug conjugates. The growth and trends of peptide drug conjugates industry provide a holistic approach to this study.
This section of the peptide drug conjugates market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
By Type
This section covers the regional outlook, which accentuates current and future demand for the Peptide Drug Conjugates market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the peptide drug conjugates market include Novartis AG, Bicycle Therapeutics, AstraZeneca, Cybrexa Therapeutics, Oncopeptides AB, Angiochem Inc., Innovasium Soricimed Biopharma, Theratechnologie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Avail customized purchase options to meet your exact research needs: